Can You Take Wegovy If You Are Diabetic?

Step 1, establishing which type of diabetes you have, and why that changes things

The starting point is straightforward, but it matters enormously. Type 2 diabetes and type 1 diabetes are biologically distinct conditions, and Wegovy's relationship with each is completely different.

For type 2 diabetes, semaglutide has a well-characterised profile. Ozempic (the lower-dose semaglutide injection) is specifically licensed for type 2 diabetes treatment in the UK, and the STEP 2 trial demonstrated meaningful weight and blood-sugar benefits in adults with type 2 diabetes using the 1mg dose. Wegovy's 2.4mg dose carries that evidence forward into the weight-management context. There is a common misconception that having type 2 diabetes rules you out of Wegovy, it does not. In practice, type 2 diabetes is one of the weight-related conditions listed in Wegovy's UK licence as a qualifying comorbidity when BMI sits between 27 and 29.9 kg/m². You can read more on the specific eligibility questions at our page covering Wegovy and type 2 diabetes.

Type 1 diabetes is a separate story. Wegovy is not licensed for type 1 diabetes, and the clinical evidence in that population is limited. Using semaglutide alongside insulin in type 1 requires specialist oversight and carries risks (including diabetic ketoacidosis in some reports) that fall outside the scope of what a weight-management prescriber can safely manage alone. If you have type 1, the right route is a conversation with your diabetologist before considering any GLP-1 treatment.

Step 2, reviewing your current diabetes medicines before anything is prescribed

This is the step that catches people out if they try to manage it alone. As Wegovy reduces appetite and body weight, blood-sugar levels often fall, sometimes significantly. That is, in one sense, a benefit. But if you are already taking medicines that lower blood sugar, particularly insulin or sulfonylureas such as gliclazide, that improvement can tip into hypoglycaemia.

A responsible prescriber will not simply add Wegovy on top of your existing regimen and leave it there. They will want to know your current HbA1c, your full diabetes medication list, and ideally liaise with your GP or diabetes team. The NHS semaglutide patient information page notes that dose adjustments to diabetes medicines may be needed once treatment starts, and this should happen with clinical oversight rather than self-managed guesswork.

Metformin alone generally carries low hypoglycaemia risk and tends to require less active adjustment, but every individual's situation differs. A prescriber needs the full picture. This is also why the clinical considerations for diabetics taking Wegovy are worth understanding in depth before your consultation.

Step 3, monitoring what changes once treatment is under way

Starting Wegovy when you have diabetes is not a set-and-forget process. Weight loss changes insulin sensitivity. Blood sugar that was previously controlled at a particular medication dose may become too well controlled as the weeks pass. Regular monitoring (whether by your GP, your diabetes nurse, or both) is part of responsible treatment.

The NHS England guidance on weight-management injections is clear that patients with complex medical backgrounds, including those on multiple diabetes medicines, benefit from close clinical follow-up throughout treatment. At nume, every repeat prescription is reviewed by a GPhC-registered Independent Prescriber before it is issued; there is no automated renewal. That said, if your diabetes is managed by a specialist team, keeping them informed is sensible practice, not a barrier to treatment, but a safeguard.

It is also worth noting that Wegovy carries a separate cardiovascular risk-reduction licence in the UK for eligible adults. If cardiovascular disease is part of your history alongside diabetes, that context is worth raising with your prescriber. You can explore the Wegovy overview for the broader picture on how the medicine is used in the UK.

What's still uncertain, and who to talk to

The evidence for Wegovy in people with type 2 diabetes and obesity is robust. The uncertainty lies at the edges: long-term outcomes for people on complex polypharmacy, the optimal sequencing of treatment when HbA1c is not well controlled, and the right approach for type 1. These are active areas of clinical discussion, not settled science.

If you have diabetes and are considering starting a weight-loss treatment, a thorough consultation is the right first step. A prescriber can only assess your suitability when they have your medical history in front of them. There is also a separate question worth considering: some people without diabetes wonder about semaglutide's metabolic effects, which we explore at can semaglutide cause diabetes and the related question of whether Wegovy can affect blood sugar in people who are not diabetic. Those are different clinical questions from this one, but they often come up together.

Pregnancy and breastfeeding are clear boundaries: Wegovy is not recommended if you are pregnant, trying to conceive, or breastfeeding, regardless of whether diabetes is part of your history. Anyone in those situations should speak to their GP. If you have questions about specific circumstances, our page on Wegovy and pregnancy covers what the guidance says.